Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a real-world study titled ‘Foslevodopa/Foscarbidopa REal-world Evidence in Parkinson’s Disease Quality of LIFE Outcomes.’ The study aims to evaluate the effectiveness of Foslevodopa/Foscarbidopa in improving the quality of life for adults with advanced Parkinson’s Disease in Italy. It also examines the impact on caregivers’ quality of life.
The intervention being tested is Foslevodopa/Foscarbidopa, an approved medication for Parkinson’s Disease, administered via subcutaneous infusion. The study involves approximately 270 participants across 19 sites in Italy.
This observational study follows a cohort model with a prospective time perspective. Participants will receive treatment as prescribed by their physicians and will be monitored for up to 12 months during routine clinical visits.
The study began on June 4, 2025, with the latest update submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The study’s outcomes could influence AbbVie’s stock performance by showcasing the real-world effectiveness of their treatment, potentially boosting investor confidence. It also positions AbbVie competitively within the Parkinson’s treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.